OBJECT: Treatment options for patients with cavernous sinus meningiomas (CSMs) include microsurgical tumor resection, radiotherapy, and radiosurgery. Gamma Knife surgery (GKS) is increasingly being used because it is associated with lower mortality and morbidity rates than microsurgery. The purpose of this study was to assess the role of GKS in the treatment of CSM and to thoroughly analyze the clinical response to GKS. METHODS: Between January 2001 and December 2005, 123 patients (25 men and 98 women; mean age 62.6 +/- 11 years, range 31-86 years) who underwent treatment for CSMs were included in this study. Of these, 41 patients underwent microsurgery before GKS, whereas the remaining 82 had GKS as a first-line therapy after a diagnosis was made based on magnetic resonance imaging findings. Dysfunction in cranial nerves (CNs) II, III, IV, V, and VI was noted in 74 patients at the time of GKS. The mean tumor volume was 7.99 cm(3) (0.7-30.5 cm(3)). The mean prescription dose to the tumor margin was 13.8 +/- 1.1 Gy (range 10-20 Gy). RESULTS: The overall tumor control rate was 98.4% with a median follow-up of 36 months. The actuarial tumor control rate at 5 years was 90.5%. A reduction in tumor volume was observed in 53 patients (43.1%), whereas in 68 patients (55.3%) no volumetric variation was recorded. Of the 74 patients who presented with CN deficits, improvement was noted in 23 (31.1%). CONCLUSIONS: Gamma Knife surgery is a useful treatment for CSM both as a first- or second-line therapy. It is a safe and effective treatment for tumors located close to the optic pathways.
OBJECT: Treatment options for patients with cavernous sinus meningiomas (CSMs) include microsurgical tumor resection, radiotherapy, and radiosurgery. Gamma Knife surgery (GKS) is increasingly being used because it is associated with lower mortality and morbidity rates than microsurgery. The purpose of this study was to assess the role of GKS in the treatment of CSM and to thoroughly analyze the clinical response to GKS. METHODS: Between January 2001 and December 2005, 123 patients (25 men and 98 women; mean age 62.6 +/- 11 years, range 31-86 years) who underwent treatment for CSMs were included in this study. Of these, 41 patients underwent microsurgery before GKS, whereas the remaining 82 had GKS as a first-line therapy after a diagnosis was made based on magnetic resonance imaging findings. Dysfunction in cranial nerves (CNs) II, III, IV, V, and VI was noted in 74 patients at the time of GKS. The mean tumor volume was 7.99 cm(3) (0.7-30.5 cm(3)). The mean prescription dose to the tumor margin was 13.8 +/- 1.1 Gy (range 10-20 Gy). RESULTS: The overall tumor control rate was 98.4% with a median follow-up of 36 months. The actuarial tumor control rate at 5 years was 90.5%. A reduction in tumor volume was observed in 53 patients (43.1%), whereas in 68 patients (55.3%) no volumetric variation was recorded. Of the 74 patients who presented with CN deficits, improvement was noted in 23 (31.1%). CONCLUSIONS: Gamma Knife surgery is a useful treatment for CSM both as a first- or second-line therapy. It is a safe and effective treatment for tumors located close to the optic pathways.
Authors: Jay Jagannathan; Adam S Kanter; Claire Olson; Jonathan H Sherman; Edward R Laws; Jason P Sheehan Journal: J Neurooncol Date: 2008-06-21 Impact factor: 4.130
Authors: Daniel Rueß; Fenja Fritsche; Stefan Grau; Harald Treuer; Mauritius Hoevels; Martin Kocher; Christian Baues; Maximilian I Ruge Journal: J Neurol Surg B Skull Base Date: 2019-03-12
Authors: Antonio Santacroce; Constantin Tuleasca; Roman Liščák; Enrico Motti; Christer Lindquist; Matthias Radatz; Brigitte Gatterbauer; Bodo E Lippitz; Roberto Martínez Álvarez; Nuria Martínez Moreno; Marcel A Kamp; Bente Sandvei Skeie; Stephanie Schipmann; Michele Longhi; Frank Unger; Ian Sabin; Thomas Mindermann; Otto Bundschuh; Gerhard A Horstmann; A T C J van Eck; Maja Walier; Manfred Berres; Makoto Nakamura; Hans Jakob Steiger; Daniel Hänggi; Thomas Fortmann; Samer Zawy Alsofy; Jean Régis; Christian Ewelt Journal: Cancers (Basel) Date: 2022-08-22 Impact factor: 6.575